[go: up one dir, main page]

PL3373910T3 - Preparat echinomycyny, sposób wytwarzania i sposób stosowania - Google Patents

Preparat echinomycyny, sposób wytwarzania i sposób stosowania

Info

Publication number
PL3373910T3
PL3373910T3 PL16864923.4T PL16864923T PL3373910T3 PL 3373910 T3 PL3373910 T3 PL 3373910T3 PL 16864923 T PL16864923 T PL 16864923T PL 3373910 T3 PL3373910 T3 PL 3373910T3
Authority
PL
Poland
Prior art keywords
echinomycin
formulation
making
echinomycin formulation
Prior art date
Application number
PL16864923.4T
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Christopher Bailey
Pan Zheng
Original Assignee
Children's Research Institute, Children's National Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Research Institute, Children's National Medical Center filed Critical Children's Research Institute, Children's National Medical Center
Publication of PL3373910T3 publication Critical patent/PL3373910T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16864923.4T 2015-11-10 2016-11-09 Preparat echinomycyny, sposób wytwarzania i sposób stosowania PL3373910T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562253257P 2015-11-10 2015-11-10
PCT/US2016/061157 WO2017083403A1 (en) 2015-11-10 2016-11-09 Echinomycin formulation, method of making and method of use thereof

Publications (1)

Publication Number Publication Date
PL3373910T3 true PL3373910T3 (pl) 2023-10-09

Family

ID=58695179

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16864923.4T PL3373910T3 (pl) 2015-11-10 2016-11-09 Preparat echinomycyny, sposób wytwarzania i sposób stosowania

Country Status (11)

Country Link
US (1) US11116726B2 (pl)
EP (1) EP3373910B1 (pl)
JP (1) JP7017018B2 (pl)
KR (1) KR20180101340A (pl)
CN (1) CN108495619A (pl)
AU (1) AU2016352874B2 (pl)
CA (1) CA3004939A1 (pl)
ES (1) ES2956013T3 (pl)
PL (1) PL3373910T3 (pl)
SG (1) SG11201803915UA (pl)
WO (1) WO2017083403A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3337491A4 (en) * 2015-08-19 2019-04-10 Children's Research Institute, Children's National Medical Center COMPOSITIONS AND METHODS FOR TREATING TRANSPLANT HOST REACTION
WO2017115358A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
DK3646854T3 (da) * 2018-10-30 2022-09-26 Polyplus Transfection Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
US20240033317A1 (en) * 2020-02-14 2024-02-01 Children's National Medical Center Uses of hypoxia-inducible factor inhibitors for treating tp53-mutated acute myeloid leukemia
CN114432328A (zh) * 2020-11-05 2022-05-06 广州中医药大学第一附属医院 一种用于治疗肝细胞癌的药物组合物及其应用
US20240139280A1 (en) * 2021-04-14 2024-05-02 OncoC4, Inc. Use of hif-1-alpha inhibitors in cancer immunotherapy
WO2024002385A1 (zh) * 2022-08-05 2024-01-04 成都华昊中天药业有限公司 棘霉素类抗生素胶束及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US5139803A (en) * 1989-02-09 1992-08-18 Nabisco, Inc. Method and liposome composition for the stabilization of oxidizable substances
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US7419683B2 (en) * 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US20160058793A1 (en) * 1999-08-30 2016-03-03 David S. Terman Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer
AU2003233480A1 (en) * 2002-04-03 2003-10-20 Montana State University-Bozeman Endophytic streptomycetes from higher plants with biological activity
GB2395097B (en) * 2002-11-07 2005-11-09 Motorola Inc A decoder apparatus and method of decoding therefor
US20040156888A1 (en) * 2002-11-26 2004-08-12 Jensen Gerard M. Liposomal formulations
JP4789208B2 (ja) * 2003-04-09 2011-10-12 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド タンパク質発現に向けられた渦巻型組成物
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
US20070105758A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
JP2010507099A (ja) 2006-10-16 2010-03-04 ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー 合成抗体
US20090053769A1 (en) * 2007-06-18 2009-02-26 University Of Southern California Heterologous production of natural products in bacteria
US20090104257A1 (en) * 2007-10-23 2009-04-23 Xingong Li Liposomal Vancomycin Formulations
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
SMT202100234T1 (it) * 2009-12-04 2021-05-07 Oncoc4 Lnc Usi di inibitori di fattori inducibili da ipossia
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
CA2816681A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
CN104144679A (zh) 2011-11-04 2014-11-12 恩瑟拉德斯医药有限公司 用于治疗人类炎症性疾病的脂质体皮质类固醇
WO2013070872A1 (en) * 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
CN103157112B (zh) 2011-12-19 2014-12-17 沈阳药科大学 唾液酸衍生物在制备peg脂质衍生物修饰制剂中的应用
US20150265642A1 (en) * 2012-10-09 2015-09-24 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
EP2968144A1 (en) 2013-03-13 2016-01-20 Mallinckrodt LLC Liposome oxaliplatin compositions for cancer therapy
WO2015017807A1 (en) 2013-08-01 2015-02-05 University Of Georgia Research Foundation, Inc. Liposomal formulations for the treatment of bacterial infections
TWI656887B (zh) * 2013-12-24 2019-04-21 國邑藥品科技股份有限公司 脂質體懸浮液及其製備方法與應用

Also Published As

Publication number Publication date
EP3373910B1 (en) 2023-07-12
EP3373910A4 (en) 2019-06-12
WO2017083403A1 (en) 2017-05-18
AU2016352874A1 (en) 2018-06-07
EP3373910A1 (en) 2018-09-19
KR20180101340A (ko) 2018-09-12
SG11201803915UA (en) 2018-06-28
ES2956013T3 (es) 2023-12-11
JP2018533628A (ja) 2018-11-15
AU2016352874B2 (en) 2021-06-24
CA3004939A1 (en) 2017-05-18
EP3373910C0 (en) 2023-07-12
JP7017018B2 (ja) 2022-02-08
US11116726B2 (en) 2021-09-14
US20180344642A1 (en) 2018-12-06
CN108495619A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
ZA201801511B (en) Flavonoid compositions and methods of use
CA3244408A1 (en) Therapeutic compositions, combinations, and methods of use
IL256621A (en) Carrier-binder preparations and methods for their preparation and use
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
PL3373910T3 (pl) Preparat echinomycyny, sposób wytwarzania i sposób stosowania
GB201514760D0 (en) Compounds and method of use
IL258139A (en) Nicotine compositions and methods for their preparation and use
PL3398598T3 (pl) Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie
IL254783B (en) Combinations for deworming methods for using them
SG11201705085UA (en) Polymer composition, its method of preparation, its use and composition comprising it
SG11201803284YA (en) Novel method of use and compositions
GB201511799D0 (en) Composition and methods of treatment
SG10201603101YA (en) Lubricant composition, and preparation method and use thereof
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
SG11201805810PA (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
PL3118240T3 (pl) Sposób otrzymywania bezizocyjanianowych polihydroksyuretanów oraz bezizocyjanianowych polihydroksyuretano-epoksydów
GB201506808D0 (en) Bottle and method of preparation thereof
GB201408171D0 (en) Formulation and method of manufacture
ZA201802201B (en) Novel formulation and treatment methods
ZA201708339B (en) Primin derivatives, method of preparation thereof and use thereof
GB201501469D0 (en) Garment and method of use thereof